Journal article
A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer
- Abstract:
-
Background In the current study, the authors sought to determine the maximum tolerated dose (MTD) of the novel class 1 selective histone deacetylase inhibitor CXD101 in a dose escalation study in patients with advanced solid tumors or recurrent/refractory lymphoma.
Methods The authors escalated the dose of CXD101 from 1 mg twice daily orally for 5 days in a 21‐day cycle (3+3 design).
Results A total of 39 patients were e... Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Bibliographic Details
- Publisher:
- Wiley Publisher's website
- Journal:
- Cancer Journal website
- Volume:
- 125
- Issue:
- 1
- Pages:
- 99-108
- Publication date:
- 2018-10-17
- Acceptance date:
- 2018-08-24
- DOI:
- EISSN:
-
1097-0142
- ISSN:
-
0008-543X
- Pmid:
-
30332497
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:929733
- UUID:
-
uuid:c83dcd5f-9a5e-4435-971e-36f833bcf4a2
- Local pid:
- pubs:929733
- Source identifiers:
-
929733
- Deposit date:
- 2019-06-24
Terms of use
- Copyright holder:
- American Cancer Society
- Copyright date:
- 2018
- Notes:
- © 2018 American Cancer Society. This is the accepted manuscript version of the article. The final version is available online from Wiley at: 10.1002/cncr.31791
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record